Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 13/20 | 1.00 |
| ▸ | ESR1 | P03372 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.74 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | SHBG | P04278 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.74 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | PDE4A | P27815 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5324130 | 1.00 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL19393201 | 1.00 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL13266169 | 1.00 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL5336088 | 0.90 | STS (0.81) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL17775797 | 0.88 | STS (0.79) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL14154435 | 0.88 | STS (0.78) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL8937142 | 0.88 | STS (0.78) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL27047081 | 0.87 | STS (0.77) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL4903619 | 0.86 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 | |
| SCHEMBL4903623 | 0.86 | STS (1.00) | STSESR1CYP3A4ESR2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583893-A1 | COMPOSITIONS AND METHODS FOR IMPROVING OVARIAN FUNCTION | Gameto, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-3518933-B2 | METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS | SUMITOMO PHARMA SWITZERLAND GMBH (CH) | 2025-02-26 | — | — | EP | disclosed |
| US-11957684-B2 | Treatment of heavy menstrual bleeding associated with uterine fibroids | SUMITOMO PHARMA SWITZERLAND GMBH (CH) | 2024-04-16 | — | — | US | disclosed |
| US-20240050625-A1 | IMPLANT FOR OVARIAN DECLINE AND METHODS OF MANUFACTURING AN IMPLANT FOR OVARIAN DECLINE | Gameto, Inc (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2024035964-A1 | COMPOSITIONS AND METHODS FOR IMPROVING OVARIAN FUNCTION | GAMETO, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| CN-116284192-B | Synthesis method of high-purity emamectin benzoate | 南雄阳普医疗科技有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-11744920-B1 | Implant for ovarian decline and methods of manufacturing an implant for ovarian decline | Gameto, Inc (US) | 2023-09-05 | — | — | US | disclosed |
| CN-116284192-A | Synthesis method of high-purity emamectin benzoate | 南雄阳普医疗科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022165097-A9 | METHODS OF ADMINISTRATING ELAGOLIX | ABBVIE INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4094766-A1 | METHODS OF TREATING UTERINE FIBROIDS AND ENDOMETRIOSIS | Myovant Sciences GmbH (CH) | 2022-11-30 | — | — | EP | disclosed |
| US-10788483-B2 | Optimization method of a polynucleotide sequence | VICTORIA LINK LIMITED (NZ) | 2020-09-29 | — | — | US | disclosed |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | LABORATORY SKIN CARE, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190255076-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS THAT REDUCE THE INCIDENCE OF INTRACEREBRAL HEMORRHAGE AND BRAIN MICROHEMMORHAGES | ZEBRAPEUTICS INC. (CA) | 2019-08-22 | — | — | US | disclosed |
| US-10023869-B2 | Bio-sensor for the detection of small molecules | Auramer Bio Limited (NZ) | 2018-07-17 | — | — | US | disclosed |
| US-20170224823-A1 | PLATINUM-CATALYZED SILICONE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY BELFAST (GB) | 2017-08-10 | — | — | US | disclosed |
| US-20170115281-A1 | OPTIMISATION METHOD OF A POLYNUCLEOTIDE SEQUENCE | VICTORIA LINK LIMITED (NZ) | 2017-04-27 | — | — | US | disclosed |
| US-20110046599-A1 | Multi-Day Delivery Of Biologically Active Substances | SAMOS PHARMACEUTICALS LLC | 2011-02-24 | — | — | US | disclosed |
| US-7538100-B2 | 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-26 | — | — | US | disclosed |
| WO-2007113204-A2 | METHOD FOR DETECTING AND CLASSIFYING ENDOCRINE DISRUPTOR COMPOUNDS | VIB VZW (BE) | 2007-10-11 | — | — | WO | disclosed |
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957684-B2 | Treatment of heavy menstrual bleeding associated with uterine fibroids | GNRHR, SHBG, FSHR | STS 3223/4885ESR1 17/4885CYP3A4 1281/4885 |
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | STS 80/4885ESR1 22/4885CYP3A4 105/4885 |
| US-20110046599-A1 | Multi-Day Delivery Of Biologically Active Substances | GUSB, SERPINA6, CD44 | STS 1776/4885ESR1 3448/4885CYP3A4 3497/4885 |
| US-10758478-B2 | Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same | CHERP, ORAI1, CA2 | STS 4605/4885ESR1 2275/4885CYP3A4 4251/4885 |
| US-20190255076-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS THAT REDUCE THE INCIDENCE OF INTRACEREBRAL HEMORRHAGE AND BRAIN MICROHEMMORHAGES | DCX, FABP7, TFPI2 | STS 4779/4885ESR1 4844/4885CYP3A4 4748/4885 |
| US-20170224823-A1 | PLATINUM-CATALYZED SILICONE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | CYP19A1, PGR, PGRMC2 | STS 185/4885ESR1 47/4885CYP3A4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.